- Getting to the Heart of the Merck-Abbott Embargo Break
- Merck: Both Sides Now
- A Public Hearing That Isn't Public
- Fighting The Flu Vaccine Critics
- Merck’s Mega-Monday Morning
- What Not To Wear At Sanofi-Pasteur
- Merck: Live Long And Prosper
- Lights, Camera, Lipitor!
- Biopharma's Bustin' Out All Over
- Friday At The Fat Fight
SPECIAL REPORT
MOST SHARED
- Stocks Overvalued, Recession Will Return: Meredith Whitney
- U.S. May Wind Up Green With Envy
- Has Twitter's Finest Hours (Seconds) Come and Gone?
- BofA Ex-Counsel: I Was 'Stunned' When I Got Fired
- Solar Emerges From A Dark Period
- Bernanke Offers Something For Everyone
- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great
- Millions May Have to Repay Part of Obama Tax Credit
- Stanford Receiver to Release Funds Of Frozen Acounts
- Warren Buffett's Berkshire Hathaway Almost Doubles Wal-Mart Holdings During Summer
- Answers to Your Questions: A Path to Economic Disaster?
- 5 Ways to Play the Chinese Markets: Analyst
- Meredith Whitney: Turns Bearish
- 3 Stock Plays on Rising College Costs
- Warren Buffett's Berkshire Hathaway Almost Doubles Wal-Mart Holdings During Summer
- Nov. 16: Unusual Volume Leaders
- Getting to the Heart of the Merck-Abbott Embargo Break
- What MGM's Sale Could Say About Value of Content
- My Ratings on Lowe's & Home Depot: Analyst
- Buffett's Berkshire Hathaway Boosts Stake in Wal-Mart
- Time Warner to Spin Off AOL on December 9
- Gates Boosts Waste Management, Coca Cola Stakes
- What's Kept Stock Rally Going? Fear, Not Confidence
- Fed to Keep Rates Low Despite Dollar's Fall: Bernanke
- Citi Shares, A Strange Indicator Of Unemployment?
- Millions Could Have to Repay Part of Obama's Tax Credit
- Hollywood Turns to Porn as Unemployment Rises
- Slideshow: US Cities With Most Underwater Mortgages
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
![]() |
So, yesterday I posited a theory that the weak American economy might be hurting sales growth of erectile dysfunction drugs.
The drugs are so pricey and may not be covered by insurance, so I wondered whether men might be cutting their pills in half and/or not filling their expensive prescriptions if they're having to tighten their belts.
I called attention to the fact that U.S. sales of Pfizer's [PFE
Loading...
()
] Viagra went down sequentially. Analysts say that happened even with a nine percent Viagra price increase during the quarter. And BMO Capital Markets' Bert Hazlett says in a research note to clients this morning that Viagra prescriptions did indeed drop by four percent in Q2.
Yesterday, GlaxoSmithKline [GSK
Loading...
()
] reported sequentially flat sales of Levitra. But revenue from that impotence pill is so small ($26 million), it really doesn't register.
Then, this morning, Eli Lilly [LLY
Loading...
()
] announced that second quarter sales of Cialis in the U.S. went up only $5 million from the first quarter. And here, too, the company acknowledges that it raised the price. Deutsche Bank's Barbara Ryan says total worldwide prescriptions of Cialis are up six percent so far this year. So, maybe Cialis--because it lasts a day-and-a-half versus Levitra and Viagra which last a few hours or so--is simply taking more market share. Lilly also recently launched a one-a-day version of Cialis.
In a "First on CNBC" interview on "Squawk Box" this morning new LLY CEO John Lechleiter said, "I don't think we've got a good read on whether the economy is affecting Cialis sales or not." And he mentioned something interesting that I wasn't aware of: "It's the only product overseas that is not price restricted, so it's a product most people pay for out of their pocket."
But my case may be bolstered by a Dr. Benjamin Brewer who writes "The Doctor's Office" column for The Wall Street Journal. Yesterday, in a piece about the economy's impact on healthcare he offered this anecdote: "I'm getting fewer fill (prescription) requests for E.D. drugs, like Viagra, too."
Who knew that erectile dysfunction drug prescriptions might be an economic indicator? I will resist trying to coin a term for that.
Questions? Comments?









